A5044309022- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Carcinogens and Genotoxicity Assessment
- Multiple Myeloma Research and Treatments
- Methemoglobinemia and Tumor Lysis Syndrome
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- DNA Repair Mechanisms
- Ginkgo biloba and Cashew Applications
- Eosinophilic Disorders and Syndromes
- Immunotherapy and Immune Responses
- 3D Printing in Biomedical Research
- Tannin, Tannase and Anticancer Activities
- Drug-Induced Hepatotoxicity and Protection
- Synthesis and bioactivity of alkaloids
- Marine Sponges and Natural Products
- Sulfur Compounds in Biology
- Advanced biosensing and bioanalysis techniques
- Cancer therapeutics and mechanisms
- Microbial Natural Products and Biosynthesis
- Histiocytic Disorders and Treatments
University of the West of England
2006-2024
Memorial Sloan Kettering Cancer Center
2018-2019
Abstract Purpose: Clinical trials of venetoclax reported negligible rates clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, select adverse events (AE), and impact dosing modifications routine practice. Experimental Design: This retrospective cohort study included 297 CLL venetoclax-treated outside academic community centers. Demographics, baseline disease...
Growing evidence suggests that the flavonoid epigallocatechin-3-gallate (EGCG), notably abundant in green tea, has health-promoting properties. We examined effect of EGCG on cell survival and apoptosis prostate cancer line PC3. Cell was reduced increased significantly with a low dose 1 µM EGCG. The ability anticancer drug cisplatin to promote enhanced by Furthermore, EGCG, both alone combination cisplatin, promoted expression pro-apoptotic splice isoform caspase 9.
Prior to introduction the clinic, pharmaceuticals must undergo rigorous toxicity testing ensure their safety. Traditionally, this has been achieved using in vivo animal models. However, besides ethical reasons, there is a continual drive reduce number of animals used for purpose due concerns such as lack concordance seen between models and toxic effects humans. Adequate any metabolites are detected can be further complicated if agent administered prodrug form, requiring source cytochrome...
Hydrogen gas (molecular hydrogen, H2) has significant effects in a range of organisms, from plants to humans. Many inert gases have been reported similar effects, and such responses may be most pronounced when cells are stressed. Xenon (Xe), for example, is well-known anesthetic. The direct targets these gases, cases, remain elusive. Myoglobin hemoglobin known their roles the transport through coordinate interactions with metals (O2, NO, CO) covalent modifications thiols (NO, H2S) amines...
Mesenchymal stem/stromal cells (MSCs) within the bone marrow (BM) are vitally important in forming micro-environment supporting haematopoiesis after myeloablative chemotherapy. MSCs known to be damaged phenotypically and functionally by chemotherapy; however, best our knowledge, persistence of genotoxic effects chemotherapy on BM has not been studied. We therefore aimed evaluate both vitro vivo, using comet micronucleus assays, focussing DNA lesions that may contribute complications patient....
Our rechallenge of cobimetinib in an Erdheim-Chester Disease (ECD) patient for the rare adverse effect, "dropped head syndrome," with a previously unexplored regimen was successful. Similar to other experiences targeted agents ECD, dosing may vary mitigate toxicity without impairing efficacy.
The regulatory 2D in vitro micronucleus (MN) assay is part of a battery tests, used to test for genotoxicity new and existing compounds before they are assessed vivo (ICH S2). MN consists monolayer cells, whereas the bone marrow (BM) setting comprises multicellular environment within three-dimensional extracellular matrix. Although follows robust protocol set out by Organisation Economic Co-operation Development (OECD) comply with bodies, some have been identified as negative genotoxicants...
Following infection or exposure to therapeutic agents, an aggressive immune response may result, termed cytokine storm (CS) release syndrome. Here the innate system becomes uncontrolled, leading serious consequences including possible death. Patients surviving CS are at greater risk for de novo tumorigenesis, but it is unclear if any specific cytokines directly responsible this outcome. De tumorigenesis has been observed in donated cells exposed following haematopoietic stem cell transplant...
Abstract Donor cell leukaemia (DCL) is a complication of haematopoietic stem transplantation where donated cells become malignant within the patient’s bone marrow. As DCL predominates as acute myeloid leukaemia, we hypothesized that cytokine storm following chemotherapy played role in promoting and supporting leukaemogenesis. Cytokines have also been implicated genotoxicity; thus, explored line model human marrow (BM) to secrete cytokines drug treatment their potential induce micronuclei....
The marine sponge Hymeniacidon perlevis is a globally distributed and invasive species with extensive filter-feeding characteristics. symbiotic relationship fostered between the sea inhabiting microorganism key in production of metabolic enzymes which focus this study. Sponge bacterial symbionts were grown on starch agar for 48hrs. Colourimetric analyses amylase conducted at 540nm using spectrophotometric plate reader. Using an X-Bridge column (3.5μM, 4.6x150mm), 80/20 acetonitrile/water...
Introduction: HTN is the most common grade ≥ 3 Ibr-associated adverse event (AE) in trials (26%) (O'Brien, Blood 2015). Meta-analysis of suggests a 2.8-fold increased risk for pts treated with Ibr (Caldeira, PLOS ONE 2019). In practice, data on incidence, management, and long term cardiovascular (CV) consequences are limited. As administered continuously incidence cumulative, this toxicity understudied. Methods: Multicenter, retrospective study CLL 420 mg at least 6 months. We collected...
<div>AbstractPurpose:<p>Clinical trials of venetoclax reported negligible rates clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, select adverse events (AE), and impact dosing modifications routine practice.</p>Experimental Design:<p>This retrospective cohort study included 297 CLL venetoclax-treated outside academic community centers....
<p>Supplemental Figure 1.</p>
<p>Supplemental Table 1 and Supplemental Figure Legends</p>
<div>AbstractPurpose:<p>Clinical trials of venetoclax reported negligible rates clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, select adverse events (AE), and impact dosing modifications routine practice.</p>Experimental Design:<p>This retrospective cohort study included 297 CLL venetoclax-treated outside academic community centers....
<p>Supplemental Figure 1.</p>
<p>Supplemental Table 1 and Supplemental Figure Legends</p>
Background: Hypertension (HTN) is the most common grade ≥ 3 Ibrutinib (Ibr)‐associated adverse event (AE) observed in clinical trials (26%) (O’Brien, Blood 2015). Meta‐analysis of trial data suggests a 2.8‐fold increased risk HTN for patients (pts) treated with Ibr vs. placebo (Caldeira, PLOS ONE 2019). In practice, regarding incidence, medication management, and long term vascular consequences Ibr‐associated are limited. As administered continuous fashion incidence cumulative, this toxicity...